Randomized controlled trialHuman
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Critical care (London, England), 2013 Jan 17. Wu J, Zhou L, Liu J and 16 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Critical care (London, England)
Published
2013 Jan 17
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Adjuvants, ImmunologicAgedAged, 80 and overFemaleHumansInjections, SubcutaneousMaleMiddle AgedProspective StudiesSepsisSingle-Blind MethodSurvival Rate
Other papers on Thymosin α-1
Systematic review / meta-analysis · 2016
The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
Journal article · 2020Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page